UBS analyst David Lai raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $88 and keeps a Neutral rating on the shares after Sanofi (SNY) announced its intention to acquire Blueprint for up to $9.5B including a contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley
- Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Neutral from Sell at Citi
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim